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Abstract: Human papillomavirus (HPV) is often transmitted through sexual partnerships. 
However, many previous HPV transmission models ignore the existence of partnerships by 
implicitly assuming that each new sexual contact is made with a different person. Here, we 
develop a simplified pair model—based on the example of HPV—that explicitly includes 
sexual partnership formation and dissolution. We show that not including partnerships can 
potentially result in biased projections of HPV prevalence. However, if transmission rates 
are  calibrated  to  match  empirical  pre-vaccine HPV prevalence, the projected prevalence 
under a vaccination program does not vary significantly, regardless of whether partnerships 
are included.  
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1. Introduction  
 
1.1. Human Papillomavirus  
 
Human Papillomavirus (HPV) infections are responsible for several gynecologic diseases, including 
abnormal cervical cytology, cervical dysplasia, cervical cancer and genital warts [1]. Cervical cancer 
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accounts for nearly 10% of all cancers in women worldwide, making it the second most common cause 
of cancer in women [2]. However, the burden is also disparate across world regions, with cervical 
cancer incidence varying from over 30 per 100,000 women per year in Africa to under 10 per 100,000 
women per year in developed countries [2]. Mortality rates for women who develop cervical cancer 
also  vary  dramatically  across  regions,  from  over  60%  in  Africa  to  about  30%  in  developed  
countries  [2].  In  Ontario,  Canada,  for  instance  (population:  13  million),  about  500  women  are 
diagnosed with cervical cancer each year and 140 women die from it [3]. 
About 75% of adults will have at least one type of HPV in their lifetime [1,3,4]. HPV DNA has 
been detected in up to 99.7% of invasive cervical cancers worldwide [5]. The association between 
HPV and cervical cancer is unique; no other major human cancer has a single necessary cause [6,7]. 
Cervical Cancer is the second most common malignant disease in women worldwide, and generally 
affects individuals at a younger age than other cancers do [8,9]. 
There  are  approximately  130  types  of  HPV,  of  which  30–40  are  transmitted  via  sexual  
contact [1,10]. Many types of HPV are carcinogenic (high-risk) including types 16 and 18 [3,11,12]. 
Some types cause genital warts, while other types are benign [3,12]. The prevalence of carcinogenic 
HPV types seems to be higher than the prevalence of non-carcinogenic types [13-16]. 
Carcinogenic HPV types are highly prevalent in Ontario women, infecting about 1 in 4 women aged 
20–24 years [17]. Although cervical cancer is the cancer most frequently associated with HPV, HPV is 
also implicated in many anal, perianal, vulvar, and penile cancers [18]. Most HPV infections do not 
cause disease;  these genital  tract  infections  are, usually, transient  lasting a few months. However, 
carcinogenic types tend to persist, especially HPV 16 [1]. HPV types 16 and 18 are the cause of  
60–72% of cervical cancers and types 6 and 11 cause genital warts [19]. Genital warts, although not 
malignant,  are  associated  with  significant  psychosocial  morbidity  and  typically  require  multiple 
physician visits for diagnosis and treatment [20,21]. 
HPV is  unlike most other sexually transmitted infections (STIs), in that infection is not highly 
concentrated in small groups of highly sexually active people, referred to as "core groups" [11]. Rather, 
HPV is very common across the population, although incidence is consistently highest in sexually 
active women less than 25 years of age and drops off with increasing age, even when adjustments are 
made for number of sexual partners [3,12,22,23]. Decreasing age of sexual debut, increasing number 
sexual  partners  and/or  concurrent  partners,  and  shortening  time  interval  between  successive 
partnerships all contribute to increasing the risk of infection [12,22-24].  
1.2. HPV Vaccination 
A multivalent vaccine that protects against infection by types 6, 11, 16 and 18 is now available [3]. 
It has been approved for females aged 9 to 26 and is most effective when given before sexual debut. 
Vaccination programs have since been implemented in Canada and other countries [25-27]. A bivalent 
vaccine protecting against types  16 and 18 is also becoming available [28]. The efficacy of HPV 
vaccines has been shown to be exceptionally high, approaching 100% [11,29]. These trials have been 
international,  blinded,  randomized  placebo-controlled clinical  trials involving thousands  of women 
without prior exposure to the virus and who are in their late teens and early 20s [1,11,23,25,30]. Int. J. Environ. Res. Public Health 2010, 7                 
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1.3. Mathematical Models of HPV 
Many mathematical models have examined the transmission of HPV and impact of various possible 
vaccination programs. They have generally found that a vaccination strategy of pre-adolescent females 
is both highly effective and highly cost-effective, in terms of reducing HPV-associated health burdens 
such as cervical cancer incidence. These have included compartmental models, deterministic models 
and stochastic models [25,27,31-33]. Traditionally, transmission models assume homogeneous mixing 
in a one-sex or heterosexual population, which implies that sexual partnerships are instantaneous and 
of zero duration: each new sexual contact is with a new person [25,31-34]. This may be a reasonable 
simplification  in  some  subgroups  of  highly  promiscuous  individuals,  however,  for  the  general 
population, this is rarely the case. More realistically, most partnerships have a nonzero length and there 
is  also  a  positive  time  gap  between  partnerships  [24].  Since  STIs  like  HPV  spread  sexually,  not 
including partnerships in a transmission model may potentially bias model projections [35,36].  
1.4. Pair Models for Sexually Transmitted Infections 
In an attempt to address this deficiency, a number of methods to incorporate sexual partnerships 
have been developed for modelling sexually transmitted infections, such as ―pair models‖ and ―pair 
approximations‖ [35,37,38]. In a pair model, the number of partnerships (pairs) is an explicit model 
variable  and  the  process  of  partnership  formation  and  dissolution  is  captured.  For  instance, 
Kretzschmar and Dietz discuss several variations on a pair model [39]. First they consider the spread of 
SI (Susceptible-Infected) infection in a pair model and compare two cases: one where every contact is 
instantaneous and with a new partner and a second pair model with nonzero partnership length. If 
partnership length is nonzero, they found that (1) infection prevalence may initially decrease even 
when R0 > 1, (2) the growth rate is lower and (3) the endemic equilibrium is higher, than in a model 
without partnership duration. It is also shown for models with nonzero partnership length that a single 
value of R0 can imply more than one possible epidemic growth rate and endemic equilibrium. (R0 is the 
basic reproductive ratio, i.e., the average number of secondary infections produced by an infectious 
person in an otherwise susceptible population.) Therefore, R0 cannot be estimated from empirical data 
on  prevalence  of  a  sexually  transmitted  infection  without  additional  information  on  partnerships. 
Kretzschmar and Dietz also found that the transmission dynamics and R0 are affected by the assumed 
partnership dynamics for HIV, in particular.  
Similarly, Dietz and Hadeler developed a simple SIS (Susceptible-Infected-Susceptible) model with 
pair dynamics [36]. The transmission dynamics in their model depend on the contact rate within a pair 
and the duration of a partnership. They find that with a partnership separation rate that is sufficiently 
large, an endemic equilibrium can persist. They derive R0 to determine the minimum intervention 
efforts required to eradicate an infection.  
These previous models show that common insights based on classical epidemiological theory using 
homogeneous  (non-pair)  mixing  models  may  no  longer  be  valid  once  pair  dynamics  are  
included  [36,37].  The  reason  why  pair  dynamics  can  impact  transmission  can  be  seen  in  several 
examples. For instance, if two individuals are both susceptible to HPV and they remain in the same 
partnership,  with  no  concurrent  partners,  then  they  can  never  be  infected.  If  a  partnership  forms Int. J. Environ. Res. Public Health 2010, 7                 
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between a susceptible and an infected person, then for a highly transmissible pathogen, the susceptible 
person will quickly become infected. From that point on, as long as both partners remain monogamous, 
additional contacts are ―wasted‖ from the point of view of the virus [35]. Moreover, if the infection is 
totally cleared by the immune system before the partnership ends then neither partner can transmit 
infection to their new partners. Such effects can slow down the spread of disease relative to what 
would occur in a homogeneous mixing model. On the other hand, if the turnover rate of partnerships is 
very high, then partnerships do not last very long and a newly infected individual may pass on infection 
to a new sexual partner before the virus clears, allowing transmission to continue.  
1.5. Outline of Paper 
In this paper, we develop and analyze a pair model for HPV transmission and vaccination, assuming 
a Susceptible-Infectious-Recovered-Susceptible (SIRS) natural history. We analyze special cases of the 
model, considering the limit as the duration of partnerships goes to zero, in order to assess the impact 
of not including partnerships on model predictions. While the model is simplified in many respects, a 
simplified model is well suited to our objective of illustrating the impact of including versus excluding 
partnerships  in  STI  transmission  models.  The  results  and  discussion  appear  in  section  2,  the 
methodology is described in section 3, and the conclusions are drawn in section 4.  
2. Results and Discussion 
The HPV pair model describes single males and females forming monogamous sexual partnerships 
at constant rate perunittime per capita. An individual is defined as single if they do not have a sexual 
partner at a given time. Within a given partnership, the number of sexual acts per year is h, and there is 
a probability of transmission from an infectious person to their susceptible partner of  per sex act. 
Transmission  can  only  happen  in  a  sexual  partnership,  and  we  consider  transmission  of  vaccine-
included carcinogenic HPV types only. A partnership breaks up at rate  perunittime. Individuals 
recover to temporary immunity at rate  perunittime and lose that immunity at rate perunittime. Males 
are recruited at rate  males perunittime (same rate for females) and die at per capita rate  perunittime. 
Susceptible females are immunized at rate  perunittimeThe model projects HPV prevalence over 
time.  Prevalence  is  defined  as  the  percentage  of  women  infected  with  HPV  at  any  given  time; 
equilibrium prevalence is defined as the prevalence at the endemic equilibrium of the model equations. 
The model is represented through a system of ordinary differential equations (see Methods) that track 
the  time  evolution  of  partnerships  and disease prevalence with  or without vaccination.  Additional 
details of the model appear in section 3, and baseline parameter values appear in Table 1. The model is 
represented schematically in Figure 1 (pair dynamics) and Figure 2 (infection dynamics).  
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Figure  1.  Schematic  of  pair  dynamics.  Single  females,  Xi,  and  single  males,  Yj,  form 
partnerships Pij at a rate , where i,j = S,I,R. These partnerships are destroyed either when 
the relationship breaks up (which occurs at a rate ) or when one partner dies (which 
occurs at a rate ).  
 
Figure  2.  Schematic  of  infection  dynamics.  Females  only  are  vaccinated,  at  a  rate   
Infection can only occur within a partnership at a rate h. Infected individuals recover at a 
rate γ and both natural and vaccine-derived immunity wane at a rate . Single females and 
males are recruited to the sexually active population at a rate .  
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This model system exhibits classical ―threshold‖ behaviour. For instance, for sufficiently low values 
of the transmission probability per sex act, , the disease prevalence is zero, but for values of  beyond 
a specific threshold value, equilibrium disease prevalence increases significantly and then appears to 
saturate as  increases further (Figure 3a). A similar pattern is seen with increasing average number of 
sex acts per year, h (Figure 3b). This ―bifurcation‖ behaviour is a typical feature of epidemic models, 
where disease transmissibility must exceed a certain threshold in order for an endemic equilibrium to 
exist. In Figure 3a, the bifurcation point for the transmission probability per sex act  is between 
0.05/act and 0.1/act. In Figure 3b, the bifurcation point for h is approximately between 25 and 50 sex 
acts per year. Vaccination has the effect of moving the bifurcation point to the right (higher threshold 
transmission rate ) and also lowering the prevalence for values of the transmission rate to the right of 
the threshold value of , which is seen in Figure 3c. The effect of vaccination on the time evolution of 
prevalence is seen in Figure 3d, where increasing rates of vaccination cause more rapid declines in 
prevalence  as  well  as  lower  long-term  (equilibrium)  prevalence.  For  sufficiently  large  coverage 
between    =  0.1/yr  and    =  0.2/yr,  the  infection  is  eradicated.  Eradication  using  relatively  low 
vaccination  rates  occurs  in  STI  transmission  models  where  natural  immunity  is  not  durable  [40]. 
Hence, this is not a surprising outcome in our model given that HPV natural immunity appears to be 
very short lived (Table 1, [14-16]). However, we emphasize that our model is a monogamous pair 
model,  hence  eradication  of  vaccine-included  strains  may  be  more  difficult  to  achieve  in  
real populations.  
In order to examine how inclusion or exclusion of partnerships affects projected prevalence, the 
dynamics of the pair model can be explored for a range of possible values of the separation rate In 
the limit as becomes very large, we recover the case of homogeneous (non-pair) mixing since the 
duration  of  partnership  becomes  zero  and  each  new  sexual  contact  is  made  with  a  new  person. 
However, as increases, the formation rate  must also be increased to ensure that the total number of 
partnerships remains constant. Otherwise, if  were to be held constant, it is not obvious whether 
changes in prevalence as increases are due to changes in the duration of partnerships per se or just 
due to a decline in total number of pairs. The relationship between and  such that the number of 
pairs  remains  constant  as    changes  can  be  obtained  from  the  equilibrium  solution  of  model 
differential equations (see Methods, Equation (14)). The case where changes as  changes such that 
the total number of pairs is constant and only the rate of partnership turnover is changing, will be 
referred to as the ― dependent‖ case. For the sake of comparison we also consider a ―fixed‖ case 
where is held constant as changes, and the number of pairs therefore declines as  increases. 
The impact of the partnership turnover rate in the ―dependent‖ case for a given value of the 
transmission rate   and frequency of sex acts  h is  very large (Figure 4). For small values  of the 
turnover  rate  ,  the prevalence is  zero because both  partners clear the infection by the time they 
separate and seek new partners. However, as the turnover rate per year increases along the horizontal 
axis,  a  threshold  is  passed  and  the  equilibrium  prevalence begins  to  grow dramatically. For large 
enough values of , the prevalence levels off and reaches its maximum value of 12%. A plausible 
(realistic) value for in younger age classes is near the baseline value of  = 2/year [24], which places 
dynamics in the regime where partnerships can impact prevalence. Hence, in this respect (for a given, 
fixed value of the transmission rate and or number of sex acts per unit time h), homogeneous mixing Int. J. Environ. Res. Public Health 2010, 7                 
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models do not accurately capture transmission dynamics and will over-predict the prevalence of a 
sexually transmitted infection. The prevalence is also very sensitive to small changes in the turnover 
rate  in  realistic  parameter  ranges  near  the  baseline  value  of    =  2/year.  In  the  ―fixed‖  case, 
prevalence  is  again  zero  for  small  values  of    (Figure  4).  As  increases,  the  prevalence  again 
increases. However, unlike the ―dependent‖ case, the prevalence begins to decrease with increasing 
. This occurs because is fixed as increases, therefore the total number of partnerships declines to a 
point that is not sufficient to support high prevalence.  
Figure  3.  Transmission  dynamics  (equilibrium  prevalence  and  time  series)  for  various 
parameter values. Baseline parameters used are,  = 1/15/yr,  = mu*N/2,  = 1/6/month,  
 = 33.66,  = 1/yr,  = 0/yr, h = 130/yr unless otherwise stated. Figure 3a shows the 
impact of transmission rate,  on prevalence. Figure 3b shows impact of average number of 
sex acts per year, h on prevalence, for and  = 0.4/act. Figure 3c shows the impact of 
transmission rate, , on prevalence for various vaccination rates , at baseline parameters. 
Vaccination rate include  = 0/yr,  = 0.05/yr,  = 0.1/yr and  = 0.2/yr. Figure 3d shows 
a  time  series  of  prevalence  for  various  vaccination  rates  introduced  at  year  300,  with 
baseline parameters and  = 0.3/act. 
    
 
 
Figure 5 is analogous to Figure 3c, where the prevalence as a function of the transmission rate is 
investigated. However, in this case, the way that the prevalence curve changes as the turnover rate 
changes is studied. The figure shows how increasing the turnover rate shifts the bifurcation point to 
the left (lower threshold transmission rate ) and also increases the equilibrium prevalence for all 
values of . Prevalence changes most rapidly for smaller values of just to the right of the bifurcation Int. J. Environ. Res. Public Health 2010, 7                 
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point. The baseline (realistic) value of  = 2/year, the threshold is at approximately  = 0.3 per sex act. 
Figure 3 confirms that projected prevalence varies depending on whether partnership dynamics are 
included, for a broader range of parameters than were explored in Figure 4.  
Figure 6 presents the case where the transmission probability is calibrated to achieve specified 
target prevalence in the pre-vaccine era, and the subsequent impact of vaccination is then projected. 
This is similar to how transmission models are often used in practice: the transmission rate parameters 
are calibrated until the prevalence in the model matches observed (empirical) prevalence pre-vaccine 
data.  For  Figure  6,  a  range  of  possible  turnover  rates  are  explored  (with  ―dependent‖  as  in  
Figure 4). For each value of the turnover rate, the transmission rate  is calibrated such that the model 
predicts  3%  prevalence  at  equilibrium  of  infection.  (The  value  of  3%  was  chosen  to  reflect  the 
approximate prevalence of high-risk HPV types 16 and 18.) Then, vaccination is introduced at a rate of 
 = 5% per year in a population that is at the equilibrium prevalence of 3%, and the subsequent time 
evolution of prevalence is graphed. The projected time evolution is almost identical for all turnover 
rates  analyzed, including both the relatively low baseline turnover rate of  = 2/year as well as very 
high turnover rates of  = 730/year (where partnerships last half a day) that approximate the pure 
homogeneous  mixing  case.  From  Figure  6,  one  can  conclude  that  homogeneous  models  do  not 
introduce inaccuracies, relative to a pair model, as long as  is calibrated to achieve specified target 
prevalence and the effect of vaccination on prevalence is the outcome of interest.  
The analyses presented in Figures 3−6 were repeated for a higher 25% prevalence, as a form of 
sensitivity analysis, and the results and were found to be qualitatively similar (results not shown). 
Figure  4.  The  impact  of  changes  in  the  separation  rate,  ,  on  percent  infected  for  
― dependent‖ and ― fixed" cases. Baseline parameters to achieve 3% prevalence include 
  =  1/15/yr,    =  *N/2,  = 2/yr = 1/6/month,  =  1/yr, h =  130/yr,  =  0.0737/act,  
 = 33.66/yr, and  = 0. For the ― dependent‖ case, the equilibrium number of pairs was 
held constant at 8,875 according to equation (14) (see methods). 
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Figure 5. Impact of transmission rate, , on prevalence for various turnover rates,  for the 
―dependent‖ case; baseline parameters  = 1/15/yr,  = *N/2,  = 1/yr, h = 130/yr,  
 = 0/yr were used. The equilibrium number of pairs was held constant at 8,875 according 
to equation (14) (see methods). 
 
Figure 6. Time series of prevalence for various turnover rates, with vaccination introduced 
at year 300 at a rate  = 0.05/yr. Baseline parameter values are as in the 3% prevalence 
case,  = 1/15/yr,  = *N/2,  = 1/yr, h = 130/yr. The transmission rate per sex act, , is 
calibrated for each turnover rate,  to achieve 3% prevalence using the ― dependent‖ 
approach.  The  equilibrium  number  of  pairs  was  held  constant  at  8,875  according  to 
equation (14) (see methods). 
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3. Methods  
The model variables are xi (the average (mean) number of single females of infection status i = S, I, 
R), yj (the average (mean) number of single males of infection status j = S, I, R), and Pij (the average 
(mean) number of pairs of infection status i = S, I, R and j = S, I, R). An individual is defined as single 
if they do not have a partner at a given time. The model equations resulting from the assumptions 
described at the beginning of Section 2 are given by 
* ( ) ( ) ( )( ) ( ) S S S I SS SI SR SS SI SR x x X x x P P P                       (1) 
* ( ) ( )( ) ( ) S S S I IS SS RS SS IS RS y y Y y y P P P                       (2) 
( ) ( )( ) ( ) I I IS II IR IS II IR x x P P P                 (3) 
( ) ( )( ) ( ) I I SI II RI SI II RI y y P P P                 (4) 
    2 SS SS RS SR SS P P P P             (5) 
    22 II II SI IS II P P h P P             (6) 
  2 IS IS IR IS P h P P              (7) 
  2 SI SI RI SI P h P P                (8) 
  2 IR IR II IR P P P               (9) 
  2 RI RI SI II RI P P P P                (10) 
   
* 2 RS RS SS IS SS II SI IS IR RI RS SR RS P P P P P P P P P P P P P                        (11) 
   
* 2 SR SR SI SS II SI IS IR RI RS SR SR P P P P P P P P P P P P                        (12) 
where 

X
*, 

Y
*,  and 

P
*  are  the  equilibrium  number  of  single  females,  single  males  and  pairs, 
respectively (see equation (14)). The formation of new partnerships is described by the function:  Int. J. Environ. Res. Public Health 2010, 7                 
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
i, j  
xiy j
xS  xI  xR  yS  yI  yR
 
xiy j
X
* Y
*  , 

i,j S,I,R  (13) 
where  is a parameter controlling the rate of partnership formation per unit time per capita. This 
function  assumes  that  the  rate  at  which  males  (respectively,  females)  of  type  i  forms  sexual 
partnerships  with  females  (respectively,  males)  of  type  j  depends  on  the  proportion  of  females 
(respectively, males) in  the population  that are of type  j. Note that the pair formation function is 
symmetric with respect to males and females.  
The quantities X*, Y*, and P* are the number of single females, single males, and pairs at the 
equilibrium of partnership dynamics, respectively. These can easily be solved from the differential 
equations for pair dynamics in the absence of infection (not shown), yielding:  

(X*,Y*,P*) 
2 2  
 2  4   
,
2 2  
 2  4   
,

 2  4   





 
(14) 
This equation has been used to write down Equations (1)-(12) under the assumption that the pair 
dynamics have equilibrated in a population where infection and vaccination are introduced. Because 
these  are  the  equilibrium  number  of  total  pairs  and  singles  regardless  of  infection  status,  the 
expressions in Equation (14) are not dependent on the vaccination rate . Using equation (14) allows 
us to reduce the original system of equations by three dimensions by substituting in for xR, yR and PRR 
wherever they appear according to equation (14) and the following relations:  

xS  xI  xR  X *  (15) 

yS  yI  yR Y *  (16)  

PSS  PSI  PSR  PIS  PII  PIR  PRS  PRI  PRR  P*  (17) 
Equations  (1)−(12)  were  solved  numerically  in  MATLAB  using  the  built-in  function  ode23tb,  an 
implementation of an implicit Runge-Kutta solver for systems of stiff differential equations, with a first 
stage that is a trapezoidal rule step and a second stage that is a backward differentiation formula of 
order two. Solving for R0 analytically is difficult due to the large dimensionality of the system of 
equations. Parameters are given in Table 1.  Int. J. Environ. Res. Public Health 2010, 7                 
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Table 1. Model parameters, values and sources. 
Symbol  Definition  3% prevalence 
scenario 
Source 
  Vaccine efficacy  95%  [11]  
  Rate at which individuals 
leave the age group of peak 
sexual activity /yr 
1/15/yr  [2,3] 
  Rate at which individuals 
are recruited into the age 
group of peak sexual 
activity /yr 
N/2  Derived (see Methods) 
  Pair break-up rate /yr  2/yr  [27] 
  Pair formation rate /yr  33.66/yr  Derived using [27]  
(see Methods) 
h  Number of sex acts /yr  130/yr  [31] 
  Transmission rate per sex 
act 
0.073/act  [41,42], calibrated  
(see Methods) 
  Rate at which females are 
vaccinated 
0.05/yr  [42], calibration  
(see Methods) 
  Infection clearance rate/yr  1/yr  [14,16,42] 
  Natural immunity waning 
rate/yr 
1/10/yr  [13,14,16] 
4. Conclusions 
The  first  conclusion  of  this  research  is  that  models  of  STI  transmission  where  partnerships  of 
nonzero duration are explicitly included in the model yield projections that will generally differ from 
models where partnerships are not explicitly included (i.e., homogeneous mixing is assumed). This 
echoes previous findings using pair models for SI and SIS infections [37,38]. In the current SIRS pair 
model, a sufficiently high partnership turnover rate (recovering the case of homogeneous mixing) was 
found to predict a higher prevalence than occurred at realistic values of partnership turnover rates.  
However, if transmission rates are first calibrated to match observed prevalence and then used to 
predict the impact of vaccination, the predictions of these two types of models will be very similar, 
which may be surprising. Homogeneous (non-pair) models often use this type of calibration approach. 
This suggests that homogeneous mixing models may suffice for modelling STI transmission if they are 
calibrated to prevalence data and only being used to predict the impact of vaccination.  
In  practical  terms,  this  means  that  the  predicted  impact  of  vaccination  policies  according  to 
homogeneous  (non-pair)  mixing  models  cannot  necessarily  be  discarded  on  grounds  that  sexual 
partnerships  have  not  been  accounted  for.  However,  we  note  that  there  are  important  aspects  of  
real-world  sexual  contact  networks  that  we  did  not  include  in  this  analysis,  such  as  concurrency 
(overlapping partnerships), stochasticity (random effects), sexual risk groups, and age structure. These Int. J. Environ. Res. Public Health 2010, 7                 
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elements have been shown to influence disease dynamics [37,38]. For instance, at low prevalence, 
stochastic effects can cause an infection to fade out, whereas the corresponding deterministic model 
cannot describe this process. However, a deterministic model was used because most previous models 
of HPV transmission are deterministic models, and our objective was to comment on the domain of 
validity of these previous HPV models. Our conclusions might also change if we were to compare 
homogeneous  mixing models  to  a more realistic sexual partnership model. We also note that this 
model did not include a ―core group‖ of highly sexually active individuals that sustain transmission and 
without  whom  the  infection  dies  out.  Further  analysis  can  explore  the  role  of  highly  active 
subpopulations  in  HPV  transmission  to  determine  whether  they  have  a  significant  impact  on 
transmission dynamics.  
Finally, a more exhaustive exploration of parameter space may reveal parameter regimes where pair 
model projections of the impact of vaccination diverge from homogeneous mixing model projections, 
even when both models are calibrated to pre-vaccine prevalence. However, the biological plausibility 
of these parameter regimes would have to be considered. Rigorous analysis of the model equations, 
permitting  a  derivation  of  the  basic  reproduction  number  R0  for  example,  would  facilitate 
understanding the relationship between model predictions and model parameters. However, derivation 
of R0 is difficult due to the large dimensionality of the system. Moreover, an expression for R0 would 
not  provide  much  information  about  the  transient  nature  of  the  solutions,  and  it  is  the  transient 
solutions that are relevant to public health since transient solutions describe prevalence in the first few 
years or decades after a vaccination program is implemented.  
Additionally, this model only considers infection from HPV types 16 and 18 since the vaccine is 
preventative for these types. However, there are 30–40 HPV types that are transmitted sexually and 
infection with certain types may inhibit or activate infection of other types. The interaction between 
HPV types, or the impact of potential highly multivalent vaccines, could also be studied in future work. 
Many of these limitations suggest areas for future research on this topic. 
In summary, if homogeneous mixing models that neglect partnerships are used to assess the impact 
of vaccination programs or other interventions for sexually transmitted infections, it is important to 
understand how and whether the non-inclusion of partnership dynamics influences the projections of 
these models. This is particularly important if these models are used to inform public health policy.  
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